Sonpavde Guru, Slawin Kevin M, Spencer David M, Levitt Jonathan M
Rev Urol. 2010 Winter;12(1):25-34.
Prostate cancer vaccines attempt to induce clinically relevant, cancer-specific systemic immune responses in patients with prostate cancer and represent a new class of targeted, nontoxic therapies. With a growing array of vaccine technologies in preclinical or clinical development, autologous antigen-presenting cell vaccines loaded with the antigen, prostate acid phosphatase, and poxvirus vaccines targeting prostate-specific antigen have recently demonstrated a significant survival benefit in randomized trials of patients with metastatic castration-resistant prostate cancer, whereas others have failed to demonstrate any benefit. The combination of vaccines with chemotherapy, radiotherapy, and other biologic agents is also being evaluated. Efforts to optimize vaccine approaches and select ideal patient populations need to continue to build on these early successes.
前列腺癌疫苗旨在诱导前列腺癌患者产生具有临床相关性的、癌症特异性的全身免疫反应，是一类新型的靶向、无毒疗法。随着越来越多的疫苗技术处于临床前或临床开发阶段，负载抗原前列腺酸性磷酸酶的自体抗原呈递细胞疫苗以及靶向前列腺特异性抗原的痘病毒疫苗最近在转移性去势抵抗性前列腺癌患者的随机试验中显示出显著的生存获益，而其他一些疫苗则未能显示出任何益处。疫苗与化疗、放疗及其他生物制剂的联合应用也在评估之中。优化疫苗方法并选择理想患者群体的工作需要在这些早期成功的基础上继续推进。
